These favorable characteristics of the EVs and Nbs strengthen our hypothesis that EVs can be bioengineered to express Trop2-specific nanobodies, allowing for a more targeted antitumor therapy for breast cancer. The gene discussed is TACSTD2; the disease is breast cancer.